Journals / İnfeksiyon Dergisi / 2004 / Cilt: 18 - Sayı: 2

Meningococcemia and meningococcal meningitis with mortal course: Case report

Penisilin allerjisi olan bir olguda meningokoksemi ve meningokok meninjiti

Pages
243–247
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, meningococcal meningitis, meningococcemia and disseminated intravascular coagulation with fatal outcome in a 21-year-old male patient with penicillin hypersensivity is presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Meningococcal meningitis is a disease seen worldwide and, despite the usage of effective antibiotics, still has a high mortality rate.
📊
Key Findings & Data:Penicillin is the first choice in the treatment.
💡
Conclusion & Impact:In this article, meningococcal meningitis, meningococcemia and disseminated intravascular coagulation with fatal outcome in a 21-year-old male patient with penicillin hypersensivity is presented.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Meningococcal meningitis is a disease seen worldwide and, despite the usage of effective antibiotics, still has a high mortality rate. Penicillin is the first choice in the treatment. In this article, meningococcal meningitis, meningococcemia and disseminated intravascular coagulation with fatal outcome in a 21-year-old male patient with penicillin hypersensivity is presented.

Özet

Meningokok meninjiti dünyanın her yerinde görülebilen, etkili antibiyotiklerin kullanılmasına karşın hala önemli derecede mortaliteye neden olan bir infeksiyon hastalığıdır. Tedavisinde penisilin ilk seçenektir. Bu makalede, penisilin allerjisi olan 21 yaşındaki bir erkek olguda görülen ve ölümle sonuçlanan meningokoksik meninjit, meningokoksemi ve yaygın damar içi pıhtılaşma tablosu sunulmuştur.

🔖

Cite This Article

TEKİN, B., GÜLER, S., URAL, O. (2022). Meningococcemia and meningococcal meningitis with mortal course: Case report. İnfeksiyon Dergisi, Cilt: 18 - Sayı: 2, 243–247. https://ajindex.com/articles/546576

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Apicella MA. Neisseria meningitidis. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill, Livingstone. 2000: 2228-41
  2. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708-16
  3. Jackson LA, Tenover FC, Baker C, et al. Prevalance of Neisseria meningitidis relatively resistant to penicilin in the United States, 1991. Meningococcal Disease Study Group. J Infect Dis 1994; 169:438-41
  4. Kuyucu N, Kunak B, Yöney A, Fışgın T. Menengokok infeksiyonlarında sonucu belirleyen prognostik göstergeler. ANKEM Derg 1997; 11: 502-6
  5. Stiehm ER, Damrosch DS. Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patients. J Pediatr 1966; 68:457-67
  6. Lodder MC, Schildkamp RL, Bijlmer HA, Dankert J, Kuik DJ, Scholten RJ. Prognostic indicators of the outcome of meningococcal disease: a study of 562 patients. J Med Microbiol 1996; 45:16-20
  7. Saez-Nito JA, Lujan R, Berron S, et al. Epidemiology and molecular basis for penicilin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1992; 14: 394S-402
  8. Feder HM, Jr Garibaldi RA. The significance of nongonococcal, nonmeningococcal Neisseria isolates from blood cultures. Rev Infect Dis 1984; 6:181-8
  9. Coşkunu Ş, Yanıkyürek S, Önlü E, Önder Y, Yücedağ G, Ergün G. Neisseria meningitidis'in antimikrobiklere karşı duyarlılığı ve kemoprofilakside rifampisinin etkisi. İnfek Derg 1990; 4:423-9
  10. Gilja OH, Halstensen A, Digranes A, Mylvaganam H, Aksnes A, Hoiby EA. Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis. Antimicrob Agents Chemother 1993; 37:2224-6.